A Phase 2 interventional study of GH001 in Bipolar II Disorder, sponsored by GH Research Ireland Limited. Terminated at 7 sites in 3 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-02-18.
Sponsored by GH Research Ireland Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Bipolar Disorder with a site in Germany — 6 open to participants now, 7 under way, 2 of them phase 3. Bipolar Disorder · Germany.
Among the 41 studies in Bipolar Disorder with a site in Germany, this one is the 35th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 2, and was the 36th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →6 of the 41 studies in Bipolar Disorder with a site in Germany are open now. Recruiting first, the newest first:
Max-Planck-Institute of Psychiatry · Sites in Germany
Ages 18–65
Dr. Inge Winter · Sites in Germany, Austria, Greece and 3 more countries
Ages 18+
Forschungsinstitut der Diabetes Akademie Mergentheim · Sites in Germany
Ages 18–80
Max-Planck-Institute of Psychiatry · Sites in Germany
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 12+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 16 · Phase 4 3
First in 2002; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 174 across the 36 interventional studies, 1,419 across the 5 observational. Of the 30 that completed or were terminated, 8 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 41 have an industry lead sponsor. The 10 most frequent:
GH Research Ireland Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.
GH Research Ireland Limited has 1 study filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies in Bipolar Disorder with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07212075Forschungsinstitut der Diabetes Akademie MergentheimPrecision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies in Bipolar Disorder with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 participants with clinically diagnosed bipolar disorder (BD) type II and experiencing a current episode of depression will be included in this study. The participants will receive an individualized dosing regimen (IDR) with at least one and up to three doses of GH001 administered within a single day.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GH001 (Mebufotenin, 5-Methoxy-N,N-Dimethyltryptamine) is administered via inhalation, as an IDR consisting of up to 3 increasing doses of GH001 (6 mg, 12 mg, and 18 mg), on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a peak experience \[PE\]) at the previously administered dose.
Drug: GH001
GH001 administered via inhalation
Also known as: 5-Methoxy-N,N-Dimethyltryptamine, 5-MeO-DMT, Mebufotenin
The anti-depressive effects of GH001 evaluated by the change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) assessed at Day 7
The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item is scored from 0 to 6. The overall score ranges from 0 to 60.
Time frame: From Baseline to Day 7
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2023 to primary completion in Nov 2024, 19 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methoxydimethyltryptamines
GH Research Ireland Limited